Gilead Sciences, Inc. (GILD), AbbVie Inc (ABBV): Which Company Needs a HCV Win?

Page 1 of 2

The upcoming all-oral hepatitis C treatments earned well-deserved attention for some staggering cure rates, particularly in patient groups who haven’t responded well to the current drugs. Merck & Co., Inc. (NYSE:MRK) was one of the big HCV players — but that’s about to change with Gilead Sciences, Inc. (NASDAQ:GILD) and AbbVie Inc (NYSE:ABBV) leading the new guard. How much does an HCV foothold mean to the overall health of these companies?

Gilead Sciences, Inc. (NASDAQ:GILD)

Defending champion falls flat

The combo therapy used for most patients with ongoing HCV involves an interferon injection and the oral drug ribavirin. But patients with genotype 1 — the most common genotype in the United States — require the addition of a protease inhibitor to achieve the best possible cure rates.

Merck & Co., Inc. (NYSE:MRK) has historically held a front position in the HCV market with the ribavirin Rebetol, the branded interferon PegIntron, and the protease inhibitor Victrelis. But generic ribavirin became available nearly a decade ago — and Merck & Co., Inc. (NYSE:MRK)’s lost most of its other ground to competitors.

PegIntron hit peak sales of $914 million in 2008 when Schering Plough was still independent. Sales last year had fallen to $653 million due to the rise of Roche’s competing Pegasys, which had 2012 sales of about $1.7 billion (using current exchange rates).

Victrelis was much faster at succumbing to competition. The drug launched concurrently with Vertex’s protease inhibitor Incivek in 2011. Incivek quickly took the market with sales of $950 million in 2011 and $1.16 billion in 2012. Victrelis had sales of $140 million and $502 million, respectively. But both protease inhibitors could suffer a massive drop when the all-oral drugs hit the market.

New guard’s drug dependence

Three companies have reported the best cure rates for genotype 1 patients: Gilead Sciences, Inc. (NASDAQ:GILD), AbbVie Inc (NYSE:ABBV), and Johnson and Johnson.

Let’s turn first to Gilead Sciences, Inc. (NASDAQ:GILD)’s sofosbuvir. The drug received a priority review designation from the Food and Drug Administration last month and has an expected PDUFA date of December 8.. Analyst estimates for sofosbuvir average out to around $6 billion by 2016, according to Bloomberg.

Gilead Sciences, Inc. (NASDAQ:GILD)’s total products sales were $9.4 billion last year and that included over a dozen products. The company’s portfolio includes a strong batch of HIV drugs, while the pipeline also features some promising cancer candidates.

AbbVie Inc (NYSE:ABBV)’s unnamed oral combo-therapy is running slightly behind Gilead Sciences, Inc. (NASDAQ:GILD) in the pipelines, but AbbVie Inc (NYSE:ABBV)’s in greater need of a win.

Page 1 of 2
Comments
Insider Monkey Small Cap Strategy
Insider Monkey Small Cap Strategy

Insider Monkey beat the market by 52 percentage points in 24 months. Our beta is only 1.2 (don't click this link if beating the market isn't important to you).

Lists

The 9 Most Expensive Designer Bags in the World

The 7 Most Expensive Real Estate in the World

The 10 Most Expensive eBay Items Ever Sold

The 10 Most Expensive iPhone Apps

The 9 Most Expensive Designer Shoes in the World

The 10 Most Expensive Cigarette Brands

The 10 Most Expensive Law Schools in the US

The 10 Best Wall Street Movies

The 10 Most Expensive Golf Clubs Ever Sold

The 10 Most Expensive Golf Memberships

The 10 Best Disney Characters Ever Created

The 8 Best Foods for Gaining Weight

The 10 Most Expensive Colleges in the World

The 7 Most Memorable Ad Campaigns of All Time

The 7 Most Expensive High Schools in the World

The 10 Electric Vehicles with the Longest Range

The 10 Cities with the Worst Drivers in the World

The 10 Most Expensive Dresses Ever Created

10 Islands to Visit Before You Die

10 Famous Celebrities Who Needed Rehab

The 15 Countries with the Largest Oil Reserves

The 10 Most Overused Excuses in the World

The 5 Best iOS Apps You Can’t Get on Android

5 Companies Damaged By Social Media Blunders

The 10 Most Legendary Blues Songs

The 10 Most Lawless Places in the World

4 Reasons China is a Threat to the US

The 17 Most Sugary Drinks in the World

The 10 Most Ruthless Rulers in History

The 10 Greatest Generals in History

Top 8 Travel Destinations for 2015

The 10 Safest Dog Breeds for Children

The 10 Most Stolen Vehicles in the US

The 7 Most Expensive Celebrity Weddings

The 10 Best LoL Teams in the World

Top 10 Worst Marketing Campaigns Ever Produced

Top 5 Diets that Help You Lose Weight

The 10 Best Ways to Stay Awake

7 Artists That Switched Musical Genres

The 10 Most Expensive Cities to Live in New Jersey

The 10 Best High Schools in New York

The 10 Countries With the Least Gender Inequality

The 6 Biggest Musician-Manager Feuds

The 10 Countries with the Cheapest Gas Prices

The 7 Most Theatrical Bands of All Time

The 8 Worst Band Breakups of All Time

The 10 Most Important South American Leaders

The 7 Most Successful Casting Show Winners

The 10 Most Peaceful Countries in the World

5 Big Reasons Communism Failed

Subscribe

Enter your email:

Delivered by FeedBurner

X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 47.6% in its first year! Wondering How?

Download a complete edition of our newsletter for free!